Results 61 to 70 of about 1,481 (180)

Rapid treatment center for depression in China: constructive reflections and transnational implications

Frontiers in Psychiatry
Enhancing the early diagnosis and standardized treatment of major depressive disorder (MDD), as advocated by the National Health Commission of China, is a key priority in the mental health initiatives of the nation.
Zhan-Ming Shi, Xing-Bing Huang, Xing-Bing Huang, Yan-Ling Zhou, Yan-Ling Zhou, Yu-Ping Ning, Yu-Ping Ning, Gabor S. Ungvari, Gabor S. Ungvari, Yu-Tao Xiang, Yu-Tao Xiang, Wei Zheng, Wei Zheng   +12 more
doaj   +1 more source

A systematic review of the print media representation of ketamine treatments for psychiatric disorders

, 2023
Background Public and patient expectations of treatment influence health behaviours and decision-making. Aims We aimed to understand how the media has portrayed the therapeutic use of ketamine in psychiatry.
Glozier, N, Kawalsky, J, Klinner, C, Loo, CK , Milton, A, Schokman, A, Stratton, E, Thornton, NLR   +7 more
core   +1 more source

Acute Safety and Efficacy of Intranasal Esketamine Spray Plus an Oral Antidepressant in Patient With Treatment-Resistant Depression From a University Hospital in Korea

BJPsych Open
Aims: There is limited real-world evidence for patients with treatment-resistant depression (TRD) receiving esketamine nasal spray in Korea. This study is aimed to evaluate the acute safety and efficacy of intranasal esketamine in patients with TRD from ...
Sang-Yeol Lee, Kyung-Joon Min, Chan-Mo Yang   +2 more
doaj   +1 more source

Treatment-resistant depression and intranasal esketamine: Spanish clinical consensus on practical aspects [PDF]

Background: Pharmacological management of major depressive disorder has traditionally relied on antidepressants targeting the monoaminergic pathway. Treatment-resistant depression (TRD) patients have been frequently excluded from registrational trials ...
Arostegui, Silvia, Cardoner, Narcís, Etxeandia Pradera, Jon Inaki, Gómez Juanes, Rocío, Gómez Revuelta, Marcos, Montes, José Manuel, Mora, Fernando, Ramos Quiroga, J. Antoni, Vieta, Eduard   +8 more
core   +4 more sources

The antidepressant effect and safety of non-intranasal esketamine:A systematic review [PDF]

, 2022
BACKGROUND: The introduction of esketamine into the field of psychiatry comes on the heels of excitement from studies on racemic ketamine. While the intranasal route has been the most studied to date, other modes of administration of esketamine may also ...
Aan Het Rot, Marije, Kamphuis, Jeanine, Schoevers, Robert A, Smith-Apeldoorn, Sanne Y, Veraart, Jolien Ke, Vischjager, Maurice   +5 more
core   +1 more source

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

Advanced Science, Volume 13, Issue 7, 3 February 2026.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang, Jiangang Xu, Xinyu Zhou, Lu Che, Minghan Qiu, Yang Liu, Ming Gao, Zhen Yang   +7 more
wiley   +1 more source

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases

European Psychiatry, 2023
Introduction Major depressive disorder (MDD) is a mental health disorder characterised by persistently low mood; anhedonia; feelings of worthlessness and guilt; altered appetite, weight and sleep and suicidal ideation. About one-third of patients do not
A. Mercado-Rodríguez, C. Martín Requena, A. Cano Baena, I. Zorrilla Martínez, A. González-Pinto Arrillaga, L. Mar-Barrutia   +5 more
doaj   +1 more source

Ketamine Combined With Psychotherapy as a Treatment for Resistant Depression in a Public European Hospital

Brain and Behavior, Volume 16, Issue 1, January 2026.
This retrospective study evaluated ketamine infusions combined with psychotherapy in nine patients with treatment‐resistant depression at a general hospital. After eight weeks, all participants improved, with PHQ‐9 scores shifting from severe to moderate. Overall, 44% responded to treatment, and among those with suicidal ideation, more than half showed
Filipa Alves da Silva, Rita Avelar, Bernardo Peixoto, Leonor Bacelar‐Nicolau, Francisco Santos, João Costa Ribeiro, Maria João Heitor   +6 more
wiley   +1 more source

Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series

European Journal of Psychotraumatology
Background: Posttraumatic stress disorder (PTSD) is a severe and frequent affection that is highly comorbid to major depressive disorder. Comorbid PTSD and depression increase the risk of treatment-resistant depression (TRD), with a high risk of ...
Maud Rothärmel, Lila Mekaoui, François Kazour, Morgane Herrero, Eva-Maria Beetz-Lobono, Aiste Lengvenyte, Jérôme Holtzmann, Philippe Raynaud, Macarena Cuenca, Samuel Bulteau, Pierre De Maricourt, Thomas Husson, Emilie Olié, Bénédicte Gohier, Anne Sauvaget, Raphaël Gaillard, Raphaëlle Richieri, David Szekely, Ludovic Samalin, Olivier Guillin, Virginie Moulier, Wissam El-Hage, Andrew Laurin, Lucie Berkovitch   +23 more
doaj   +1 more source

Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression

Brain Sciences, 2023
Psychotic treatment-resistant depression is a complex and challenging manifestation of mood disorders in the clinical setting. Psychotic depression is a subtype of major depressive disorder characterized by mood-consistent hallucinations and/or delusions.
Maria Gałuszko-Węgielnik, Zuzanna Chmielewska, Katarzyna Jakuszkowiak-Wojten, Mariusz S. Wiglusz, Wiesław J. Cubała   +4 more
doaj   +1 more source